Nandrolone Phenylpropionate is indicated-

• As an adjunct to specific therapies and dietary measures in pathologic conditions characterized by a negative nitrogen balance
• For the palliative treatment of selected cases of disseminated mammary carcinoma in women
• Osteoporosis.

As an adjunct to specific therapies and dietary measures in pathologic conditions characterized by a negative nitrogen balance: Recommended dose is 25-50 mg every week.

For the palliative treatment of selected cases of disseminated mammary carcinoma in women: Recommended dose is 50 mg every week.

Osteoporosis: Recommended dose is 50 mg every week.

For an optimal therapeutic effect it is necessary to administer adequate amounts of vitamins, minerals and protein in a calorie-rich diet. Nandrolone Phenylpropionate should be administered by deep intramuscular injection.

Contraindicated in Pregnancy, Known or suspected carcinoma of the prostate or breast in the male.

High dosages, prolonged treatment and/or too frequent administration may cause:

• Virilisation which appears in sensitive women as hoarseness, acne hirsutism and increase of libido; in prepubertal boys as an increased frequency of erections and phallic enlargement, and in girls as an increase of pubic hair and clitoral hypertrophy. Hoarseness may be the first symptom of vocal change which may end in a long-lasting, sometimes irreversible deepening of the voice.
• Amenorrhoea.
• Inhibition of spermatogenesis.
• Premature epiphyseal closure.
• Fluid retention.

Overdose Effects

The acute toxicity of Nandrolone Phenylpropionate in animals is very low. There are no reports of acute overdosage with Nandrolone Phenylpropionate in the human

If signs of virilisation develop, discontinuation of the treatment should be considered, Preferably in consultation with the patient.

It is recommended to monitor patients with any of the following conditions:

• latent or overt cardiac failure, renal dysfunction, hypertension or migraine (or a history of these conditions), since anabolic steroids may occasioally induce fluid retention:
• incomplete statural growth, since anabolic steroids in high dosages may accelerate epiphyseal closure;
• skeletal metastases of breast carcinoma. In these patients
• hypercalcaemia may develop both spontaneously and as a result of anabolic steroid therapy. The later can be indicative of a positive tumour response to the hormonal treatment. Nevertheless, the hypercalcaemia should first be treated appropriately and after restoration of normal calcium levels hormone therapy can be resumed;
• liver dysfunction.

The use of anabolic steroids to enhance athletic ability may carry severe risks to the user's health and should be discouraged.

Pregnancy & Lactation

This medicine is contraindicated durin